Patents by Inventor Bingyang GE

Bingyang GE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof
    Patent number: 10961222
    Abstract: Provided are a chemical compound of an isocitrate dehydrogenase inhibitor, and an application thereof, belonging to the field of medicinal chemistry; specifically provided is the chemical compound represented by formula I, or its isomer, pharmaceutically acceptable salt, crystal, solvate, or prodrug, as well as their preparation methods and pharmaceutical compositions containing said chemical compound, and an application of said chemical compound or composition. The chemical compound has very good ability to inhibit mutant IDH2 enzyme activity and to inhibit mutant IDH2 neoplastic cells, and may be used for preventing and/or treating a tumor characterized by the presence of mutant IDH2.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: March 30, 2021
    Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong Wang, Liwen Zhao, Xiaorong Liu, Yan Zhang, Dandan Huang, Chunhuan Jiang, Xinsheng Shi, Hongfeng Gu, Silin Pang, Wei Hai, Bingyang Ge
  • CHEMICAL COMPOUND OF ISOCITRATE DEHYDROGENASE INHIBITOR, AND APPLICATION THEREOF
    Publication number: 20190161473
    Abstract: Provided are a chemical compound of an isocitrate dehydrogenase inhibitor, and an application thereof, belonging to the field of medicinal chemistry; specifically provided is the chemical compound represented by formula I, or its isomer, pharmaceutically acceptable salt, crystal, solvate, or prodrug, as well as their preparation methods and pharmaceutical compositions containing said chemical compound, and an application of said chemical compound or composition. The chemical compound has very good ability to inhibit mutant IDH2 enzyme activity and to inhibit mutant IDH2 neoplastic cells, and may be used for preventing and/or treating a tumor characterized by the presence of mutant IDH2.
    Type: Application
    Filed: July 20, 2017
    Publication date: May 30, 2019
    Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong WANG, Liwen ZHAO, Xiaorong LIU, Yan ZHANG, Dandan HUANG, Chunhuan JIANG, Xinsheng SHI, Hongfeng GU, Silin PANG, Wei HAI, Bingyang GE